Bowel Disorders Evaluation Rule-out Cascade

Applying exclusionary criteria to assist diagnosis

Disorders of the lower gastrointestinal tract in adults and children are among the most common conditions and may pose a difficult diagnostic problem. Approximately 1 in 20 of all general practitioners' consultations involve these conditions, and their symptoms are often ill-defined.¹ Those disorders include a wide range of pathologic conditions, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) that includes Crohn's disease (CD), ulcerative colitis (UC), and indeterminate colitis; microscopic colitis, infectious colitis, small intestinal bacterial overgrowth, celiac disease and colon neoplasia (including colon cancer).²

The most prevalent condition is IBS. It is estimated that, in Europe and North America 10% to 15% of the population is affected.³ Studies show that the incidence rate of Crohn's disease increased from 0.1 (three decades ago) to 4.6 (in 2003) per 100,000 children, and the incidence of UC from 0.5 to 3.2 per 100,000 children.⁴ The prevalence of IBD among adults is approaching 0.3%.⁵ Studies have shown that the prevalence of celiac disease increased at least four times during the last 50 years and approaches 1%.⁶⁻⁸ It is estimated that less than 5% of celiac disease cases in the US are currently diagnosed.⁸

Recently, another condition termed "gluten sensitivity," distinct from celiac disease, emerged as an important and often underdiagnosed and undertreated disease. 8.9 It is reported that as much as 12% of the healthy population may have serological evidence of gluten sensitivity. 9

Difficulties in differential diagnosis of those conditions often prompt clinicians to use an exclusion approach by performing tests to rule out the alternative etiologies.² Interestingly, one study shows that most of the celiac disease serological test requests now come from general practitioners rather than gastroenterologists.¹⁰ Another study reports that 72% of general practitioners endorsed IBS as a diagnosis of exclusion.² The "gold standard" for diagnosing many of these conditions continues to be endoscopy with biopsies for histological examination.¹¹ In recent years, however, the introduction of several tests for new serological markers may allow for a reduction in the number of intestinal biopsies.¹²

To assist clinicians—through the use of exclusionary criteria—in diagnosing bowel disorders, Labcorp has introduced the **Bowel Disorders Evaluation Rule-out Cascade [164119]**. (This profile is intended to be used only in conjunction with other clinical and laboratory findings as an aid in diagnosis.)

Bowel Disorders Cascade

STEP 1: Celiac Disease Screen

The cascade begins with a celiac screen that includes testing for tTG IgA and DGP IgG. When the result is positive, testing stops and the interpretive comment on the report would read:

• Suggestive of celiac disease or other gluten-sensitive enteropathies. Subsequent testing for **Endomysial Antibody, IgA**[164996] and/or genetic testing for **Celiac HLA DQ Association** [167082] may be indicated for further patient evaluation.

The Celiac Disease Screen may be negative if the patient is on a gluten-free diet because antibodies to tTG and DGP are usually no longer present. ^{12,13} A gluten challenge would be necessary to avoid false-negative results. Genetic testing for HLA DQ2/DQ8 may be considered if the patient does not wish to undergo a gluten challenge. A negative genetic test result effectively rules out celiac disease. ^{13,14} A positive genetic test result increases suspicion of celiac disease but is not diagnostic. A positive endomysial antibody test is highly specific for celiac disease. When the result is negative, then testing reflexes to the second step.



STEP 2: Inflammatory Bowel Disease (IBD) Screen

Inflammatory bowel disease screen includes testing for IgG antibodies to anti-Saccharomyces cerevisiae (ASCA), and atypical perinuclear antineutrophil cytoplasmic antibodies (pANCA). This panel of tests will aid in serological identification of patients with IBD and in differentiation between its three clinical forms: CD, UC, and indeterminate colitis. When the marker of CD (ASCA IgG) is positive, the clinical sensitivity for CD is reported to be as high as 74.4% and specificity for IBD generally is reported to be as high as 95.9%. When atypical pANCA (a marker of UC) is positive, the clinical sensitivity for UC is reported to be as high as 70% and the specificity as high as 80%. The results of the ASCA and pANCA markers cannot rule out inflammatory bowel disease; neither can their presence strictly confirm its diagnosis. To

Testing for step two is described below and the interpretive comment on the report would be one of the following (depending on the combination of results): When ASCA IgG is positive and atypical pANCA is negative, testing stops and the comment would read:

Suggestive of Crohn's disease. Subsequent testing with the Crohn's Disease Prognostic Profile [162020] that includes
antiglycan antibodies AMCA, ALCA, ACCA, and gASCA may aid in the differentiation of clinical forms of CD and prognosis
of disease progression.

When ASCA IgG is negative or equivocal and atypical pANCA is positive, testing stops and the comment would read:

Suggestive of ulcerative colitis.

When both ASCA IgG and atypical pANCA are positive, testing stops and the comment would read:

Suggestive of IBD. Subsequent testing with the Crohn's Disease Prognostic Profile [162020] that includes antiglycan
antibodies AMCA, ALCA, ACCA, and gASCA may aid in the differentiation of clinical forms of IBD and prognosis of disease
progression.

When all results are negative, testing reflexes to the third step.

STEP 3: Non-Celiac Gluten Sensitivity Screen

The non-celiac gluten sensitivity screen includes testing for IgG antibodies to native gliadin with reported clinical sensitivity of up to 87% (for untreated clinically defined celiac disease patients and specificity of up to 91%. Recent reports show that there is a significant subset of patients that has normal histology for celiac disease, (HAS) negative for antibodies to DGP and tTG, (HAS) positive for antigliadin antibodies, and ARE clinically undistinguishable from those with celiac disease. Those patients constitute the so-called non-celiac "gluten sensitivity" group and many of them will benefit from gluten-free diet. This group of patients is also reported to have increased mortality. When the result is positive, testing stops and the interpretive comment on the report would read:


• Suggestive of non-celiac gluten sensitivity. The patient may benefit from a gluten-free diet.

When all results are negative, testing stops and the interpretive comment on the report would read:


Suggestive of irritable bowel syndrome (IBS). Careful evaluation of the patient's history, physical examination, and application of Rome III diagnostic criteria may help to rule in or rule out the diagnosis of IBS. Subsequent testing for Calprotectin, Fecal [123255] may be recommended. If IBD is strongly suspected, subsequent testing with the Crohn's Disease Prognostic Profile [162020] that includes antiglycan antibodies AMCA, ALCA, ACCA, and gASCA may aid in differential diagnosis.




STEP1 Celiac Disease Screen (Simultaneous Detection of tTG IgA and DGP IgG)



STEP 2 Inflammatory Bowel Disease (IBD) Screen (ASCA IgG, Atypical pANCA)



STEP 3 Nonceliac Gluten Sensitivity Screen (Antigliadin IgG)



Suggestive of irritable bowel syndrome (IBS). Careful evaluation of the patient's history, physical examination and application of Rome III diagnostic criteria may help to rule in or rule out the diagnosis of IBS. Subsequent testing for Calprotectin, Fecal [123255] may be recommended. If IBD is strongly suspected, subsequent testing with the Crohn's Disease Prognostic Profile [162020] that includes antiglycan antibodies AMCA, ALCA, ACCA and gASCA may aid in differential diagnosis.

Note: Biopsy with histological evaluation remains the "gold standard" for the diagnosis of many bowel disorders.



Ordering Information

Test Name	Test No.	Specimen	Container	Storage	Methodology
Bowel Disorders Evaluation Rule-Out Cascade	164119	Serum: 1mL Minimum: 0.5 mL	Red-top tube, gel-barrier tube or serum transfer tub	Room temperature	Enzyme Immunoassay (EIA)

Relevant Assays

Test Name	Test No.	Specimen	Container	Storage	Methodology
Calprotectin, Fecal	123255	Stool (unpreserved, random): 1g Mimimum: 0.5g	Clean screw-capped plastic vial	Do not contaminate outside of container; do not overfill container. Loose stools are acceptable. Preferred shipping temperature is frozen.	Chemiluminescence
Celiac HLA DQ Association	167082	Whole blood: 7 mL or four buccal swabs Mimimum: 3mL or four buccal swabs	Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). If submitting buccal swabs, please use the kit provided by Labcorp	Room temperature; protect from extreme heat or cold	PCR/sequence-specific oligonucleotide probes (Luminex)
Crohn's Disease Prognostic Profile	162020	Serum: 1mL Minimum: 0.2 mL	Red-top tube, gel-barrier tube or serum transfer tub	Room temperature	Enzyme immunoassay (EIA)
Endomysial Antibody, IgA	164996	Serum: 1mL Minimum: 0.3 mL	Red-top tube, gel-barrier tube or serum transfer tub	Refrigerate	Indirect fluorescent antibody (IFA)
Inflammatory Bowel Disease (IBD) Expanded Profile	162045	Serum: 1mL Minimum: 0.5 mL	Red-top tube, gel-barrier tube or serum transfer tub	Refrigerate	Enzyme immunoassay (EIA) for ACCA, ALCA, AMCA, gASCA; indirect fluorescent antibody (IFA) for atypical pANCA

For the most current information regarding test options, including specimen requirements and CPT codes, please consult the online Test Menu at Labcorp.com.

- 1. Rubin G, De Wit N, Meineche-Schmidt V, et al. The diagnosis of IBS in primary care: Consensus development using nominal group technique. Family Prac. 2006; 23:687-692.
- 2. Spiegel BMR. Do physicians follow evidence-based guidelines in the diagnostic work-up of IBS? Nature Clinical Practice. Gastroenterology Hepatology. 2007 Jun; 4(6):296-297.
- 3. World Gastroenterology Organization Global Guideline. Irritable Bowel Syndrome: A Global Perspective. April 20, 2009.

 4. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. Inflammatory bowel disease in children and adolescents: Recommendations for diagnosis The Porto Criteria. J Pediatric Gastroenterol Nutr. 2005 Jul; 41(1):1-7.
- 5. Carter MJ, Lobo AJ, Travis SPL, on behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53(Suppl V):v1-v16.
- 6. Celiac Disease News. Available at: http://www.celiac.nih.gov/NewsletterSpring09.aspx. Accessed August 24, 2009. 7. Green PHR, Cellier C. Celiac disease. N Engl J Med. 2007 Oct 25; 357(17):1731-1743.
- 8. Green PHR. Mortality in celiac disease, intestinal inflammation, and gluten sensitivity. JAMA. 2009 Sep 16; 302(11):1225-1226.
- 9. Hadjivassiliou M, Grinewald RA, Kandler RH, et al. Neuropathy associated with gluten sensitivity. *J Neurol Neurosurg Psychiatry*. 2006; 77:1262-1266.

 10. Evans K, Malloy AR, Gorard DA. Changing patterns of coeliac serology requests. Alimentary Pharmacology & Therapeutics. http://www.medscape.com/viewarticle/703618_print. Accessed October 16, 2009.

 11. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behavior. *Gut*. 2007; 56:1394-1403.
- 12. INOVA Diagnostics Inc. *QUANTA Lite™ h-tTG/DGP Screen*. April 2007. Revision 0.
- 13.Snyder CL, Young DO, Green PHR, Taylor AK. Celiac disease. GeneReviews. Available at: www.genetests.org. Accessed March 16, 2011.
 14. Sollid LM, Lie BA. Celiac disease genetics: Current concepts and practical applications. *Clin Gastroenterol Hepatol*. 2005; 3(9):843-851.
 15. INOVA Diagnostics Inc. *Quanta Lite™ ASCA (S cerevisiae) IgG*. May 2005. Revision USA7.
- 16. Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin Vaccine Immunol. 2006 Jun; 13(6):655-660.
- 17. Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: Gadget or magic? World J Gastroenterol. 2007 Apr 14; 13(14):2028-2036. 18. INOVA Diagnostics Inc. Quanta Lite™ Gliadin IgG. April 2005. Revision USA11.

Additional Related Studies

Ball AJ, Hadjivassiliou M, Sanders DS. Is gluten sensitivity a "No Man's Land" or a "Fertile Crescent" for Research? Am J Gastroenterol. 2010 Jan; 105:222-223. Ford R. Which serological tests best identify gluten reactions? Available at: http://www.drrodneyford.com

Wangen S. Testing for non-celiac gluten intolerance. Available at: http://www.IBSTreatmentCenter.com. Accessed August 27, 2010.

